Navigation Links
Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
Date:3/10/2011

combination with docetaxel and prednisone (Phase III).  An interim analysis is expected to be conducted by an Independent Data Monitoring Committee in mid 2011; final results are anticipated in 2012.
  • AFFIRM: First-line treatment in metastatic colorectal cancer in combination with 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX) (Phase II).  Final results are expected during the second half of 2011.

  • About Aflibercept Aflibercept (VEGF Trap) is an investigational angiogenesis inhibitor with a unique mechanism of action.  This fusion protein binds all forms of Vascular Endothelial Growth Factor-A (VEGF-A), as well as VEGF-B and placental growth factor (PIGF), additional angiogenic growth factors that appear to play a role in tumor angiogenesis and inflammation.  Aflibercept has been shown to bind VEGF-A, VEGF-B and PlGF with higher affinity than their natural receptors.

    About Non-Small Cell Lung Cancer (NSCLC)According to the World Health Organization, lung cancer is the leading cause of cancer-related deaths among men and women (1.4 million in 2008) world-wide.(1)  Lung cancer is classified as either small cell or non-small cell (most common form).(2)  Non-small cell lung cancer typically grows at a slower rate than small cell lung cancer.(3)

    About sanofi-aventis Oncology Based in Cambridge, Massachusetts, and Vitry, France, sanofi-aventis Oncology is translating science into effective cancer therapeutics to address unmet medical needs for patients with cancer.  Starting with a deep understanding of the mechanisms by which cancer develops, grows and spreads, the company employs innovative approaches in drug discovery, clinical development and partnerships to bring the right medicines to the right patients with the goal of helping cancer patients live healthier and longer lives.

    Sanofi-aventis Oncology is committed to the pursuit of science and innovative cancer thera
    '/>"/>

    SOURCE Regeneron Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
    2. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
    3. Sanofi-aventis Stands Behind the Safety of Lantus(R)
    4. Fovea Pharmaceuticals to be Acquired by sanofi-aventis
    5. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
    6. Prasco Enters into Agreements with sanofi-aventis U.S. to Provide Sales Support and Distribution Services for Authorized Generic Versions Under the Winthrop Label in U.S.
    7. Sanofi-aventis Obtains Antitrust Clearance in Connection With Chattem, Inc. Tender Offer
    8. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
    9. Sanofi-aventis Commences Tender Offer for All Outstanding Shares of Chattem, Inc.
    10. Sanofi-aventis to Acquire Chattem Inc., Creating a Strong U.S. Consumer Healthcare Platform
    11. Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/4/2015)...  Kannalife Sciences, Inc. ("Kannalife") announces that Dr. ... Board to assist the Company in the advancement of ... cannabinoid therapeutics for the treatment of Chronic Traumatic Encephalopathy ... conducting the full autopsy of Mike Webster , ... Pittsburgh Steelers. It was through his examination of ...
    (Date:3/4/2015)... Ga., March 4, 2015  Halyard Health, Inc. (NYSE: ... and provided its 2015 outlook and related key planning ... Halyard Health as we report our fourth quarter results, ... Chairman and CEO. "We executed a smooth separation from ... the spin-off. We delivered sales growth and margin improvement ...
    (Date:3/4/2015)... , March 4, 2015  ECR Booth #317/Expo ... ) is showcasing a full spectrum of X-ray imaging ... quality, reduce costs, and enable greater patient throughput for ... imaging systems.  These solutions are on display at the ... Vienna, Austria this week.   ...
    Breaking Medicine Technology:Kannalife Sciences, Inc. Announces the Addition of Dr. Bennet Omalu, Renowned Pathologist and Founder of Chronic Traumatic Encephalopathy, to its Scientific Advisory Board 2Kannalife Sciences, Inc. Announces the Addition of Dr. Bennet Omalu, Renowned Pathologist and Founder of Chronic Traumatic Encephalopathy, to its Scientific Advisory Board 3Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 2Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 3Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 4Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 5Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 6Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 7Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 8Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 9Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 10Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 11Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 12Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 13Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 14Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 15Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 16Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 17Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 18Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 19Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 20Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 21Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 22Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 23Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 24Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 25Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 26Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 27Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 28Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 29Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 30Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 31Varian Medical Systems to Showcase New X-Ray Imaging Components at the European Congress of Radiology (ECR) Annual Meeting 2Varian Medical Systems to Showcase New X-Ray Imaging Components at the European Congress of Radiology (ECR) Annual Meeting 3
    ... 2011 Argos Therapeutics, Inc. today announced that its late ... awarded the Nobel Prize in medicine for the discovery of ... Dr. Steinman,s discovery of dendritic cells and his research ... in adaptive immunity have led to the development of Argos, ...
    ... Today, Children,s Hospital at Scott & White , the ... facility between Dallas and Austin, opened its doors to patients. ... state-of-the-art Simulation Center for a mock transport of "patients" from ... White Hospital-Temple, before moving patients to the new Children,s Hospital ...
    Cached Medicine Technology:Argos Therapeutics' Late Scientific Co-founder Ralph Steinman, M.D., Awarded Nobel Prize in Medicine for Discovery of Dendritic Cells as Critical Sentinels of Immune System 2Children's Hospital at Scott & White Opens 2Children's Hospital at Scott & White Opens 3Children's Hospital at Scott & White Opens 4
    (Date:3/4/2015)... (PRWEB) March 04, 2015 RapidScale, a ... in Las Vegas, Nevada, on March 16th-18th. They are ... will have some of its top engineering executives in ... in the RapidScale solution set. Attendees include William Hiatt, ... Cloud Engineer; and Ryan Turpin, Cloud Support Manager. ...
    (Date:3/4/2015)... SIGVARIS proved innovative when they ... compression therapy collection designed exclusively for men. Building ... is proud to announce the launch of three additional ... from a unique, extremely fine synthetic fiber, MIDTOWN MICROFIBER ... and thigh-highs offer a tailored look that is perfect ...
    (Date:3/4/2015)... (PRWEB) March 04, 2015 The ... discussion leaders for its upcoming fifth annual Advanced ... Paris, France. The event this year will feature ... than 20 of the field’s leading companies and ... together top executives and clinical researchers from the ...
    (Date:3/4/2015)... Jeannie Mai, TV personality, fashion maven, and co-host of ... the print publication. Mai embraces the overall theme of the ... clothes and personal care products. In an exclusive interview, Olympic ... an organic diet. She mentions, “Having an organic lifestyle has ... also now as I’m a full time student at New ...
    (Date:3/4/2015)... (PRWEB) March 04, 2015 i2i ... been selected by Chase Brexton Health Care, a ... today. , Chase Brexton provides comprehensive primary care, ... 30,000 patients across seven clinics in the greater ... of electronic medical records, the organization has always ...
    Breaking Medicine News(10 mins):Health News:Rapidscale to Host First Cloudtalk Events at Channel Partners in Las Vegas 2Health News:Rapidscale to Host First Cloudtalk Events at Channel Partners in Las Vegas 3Health News:Building on the Success of MIDTOWN MICROFIBER, SIGVARIS Expands Popular Compression Collection with Longer Foot Length Offerings 2Health News:The Alliance for Regenerative Medicine Announces Agenda for Upcoming Advanced Therapies Summit 2Health News:The Alliance for Regenerative Medicine Announces Agenda for Upcoming Advanced Therapies Summit 3Health News:Chase Brexton Selects i2i Systems Population Health Management Solutions to Demonstrate HEDIS Quality Outcomes to Maryland’s Health Plans 2Health News:Chase Brexton Selects i2i Systems Population Health Management Solutions to Demonstrate HEDIS Quality Outcomes to Maryland’s Health Plans 3
    ... eating dietary fiber specifically from fruits and cereals lowers ... // a connection between higher intake of fiber and ... actually looked at the dietary fiber from different sources ... study researchers analyzed several studies to determine whether the ...
    ... , medication errors that occur in pediatric intensive care units ... ,Researchers studied more than 11,800 children who were admitted into ... errors. They defined an error as any preventable event that ... medical errors were reported during the course of the study. ...
    ... A new study shows weight gain after age 18 can ... women who // are not taking hormone replacement therapy. ... to 74, by asking them about their weight at age ... been periodically asked to provide updates on their weight, in ...
    ... lose significant bone mass in the first year after the ... their bodies from rejecting the new organ. The bone loss ... of fractures among this group ranges from 22 percent to ... treatment, but which drugs work best in this situation is ...
    ... a recent study conducted researchers suggest that kids who ... having their tonsils and adenoids out. ,Adenotonsillectomy is ... of the time, it is performed to treat recurring ... have also used the surgery to treat obstructive sleep ...
    ... strikes men between 20 and 34 years old. Advances ... improved survival rate from the cancer, but since men ... the effect of the cancer and its treatment on ... treatment reduces fertility, others have found fertility rates unchanged. ...
    Cached Medicine News:
    ...
    Pre-set guard for precise depth incision, bi-directional blade can cut left or right. 250 micron....
    ...
    Tips are sharp on both sides to puncture, cut and tear the capsule...
    Medicine Products: